Role of Gut Microbiome in HIV/Opioid Induced Peripheral Neuropathy
肠道微生物组在 HIV/阿片类药物引起的周围神经病变中的作用
基本信息
- 批准号:10407591
- 负责人:
- 金额:$ 46.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-15 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:Absence of pain sensationAnalgesicsAnti-Retroviral AgentsAttenuatedBackBacterial TranslocationBeta-glucuronidaseBlood CirculationCellsChronicComplicationDataDevelopmentDoseEnteralEnzymesEpithelial CellsExhibitsExposure toFunctional disorderGenetic EngineeringGlucuronidesGlucuronosyltransferaseHIVHIV InfectionsHIV SeropositivityHIV neuropathyHIV-1HyperalgesiaImmuneInfectionInterleukin-6Knockout MiceKnowledgeLoxP-flanked alleleMammalsMetabolic PathwayMicrogliaMorphineMorphine DerivativesMusNeurologicNociceptive StimulusOpioidOpioid AnalgesicsOpioid abuserPainPain managementParentsPathway interactionsPatientsPeripheralPeripheral Nervous System DiseasesPharmaceutical PreparationsPopulationPrevalenceRecyclingReportingRodentRoleSerumSignal TransductionSmall IntestinesTLR2 geneTestingTherapeuticThermal HyperalgesiasTissuesToxic effectZidovudineantagonistbacterial communitybasecommensal bacteriacytokinedysbiosisgastrointestinal epitheliumgut microbiomegut microbiotainhibitorintestinal barrierknock-downmechanical allodyniamicrobialmicrobial communitymorphine-3-glucuronidemorphine-6-glucuronidenon-drugnon-nucleoside reverse transcriptase inhibitorsopioid abuseopioid useopioid userpainful neuropathypreservationreconstitution
项目摘要
Project Summary
Prolonged use opioids results in a paradoxical increase in atypical pain (hyperalgesia). Despite its known
limitations, mechanisms underlying opioid-induced hyperalgesia still remains a significant gap in knowledge.
Peripheral neuropathy has become the most common neurologic complication in HIV patients, with prevalence
as high as 69.4% in infected patients, Notably, HIV-infected opioid abusers appear to exhibit more severe
neuropathy than HIV-infected non-drug users. Furthermore, repeated use of opioid analgesics are reported to
promote neuropathic pain in HIV patients. Very little is known if ART contributes to peripheral neuropathy and if
it is exacerbated in chronic opioid users. The main metabolic pathway for morphine and morphine derivatives
in mammals is glucuronidation catalyzed by UDP-glucuronosyltransferase (UGT) enzymes. Morphine is
metabolized predominantly to two metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide
(M6G) (1,2). M-3-G is the only metabolite produced in rodents and does not have any analgesic effects but have
been shown in recent studies to activate and modulate TLR signaling. Furthermore, antiretroviral drugs
particularly, intergrase inhibitors, are also metabolized through the UGT- glucuronidation pathway. Recent
studies show that the metabolites of the intergrase inhibitor zidovudine to be more toxic than the parent
compound. In preliminary data we show that chronic morphine treatment results in significant gut microbial
dysbiosis with significant decrease in bacterial communities that synthesize β-glucuronidase with a concurrent
decrease in glucuronidase activity. We show in preliminary data that depletion in the bacterial communities
involved in the synthesis of β -glucuronidase results in a) increased accumulation M-3-G in the gut and serum
and b) reduced enterohepatic recycling of morphine. We further demonstrate that morphine treatment in the
context of HIV infection results in significant hyperalgesia in the both the Mechanical allodynia (Von Frey) and
Thermal hyperalgesia test (Hargraves) tests. Proinflammatory cytokine levels and morphine induced
hyperalgesia are significantly attenuated in TLR2 knock out mice. Based on these observations we hypothesize
that decreased microbial communities associated with β glucuronidase synthesis following prolonged
exposure to high dose morphine results in accumulation of M-3-G morphine metabolite and toxic
glucuronidated ART in the small intestine contributing to Specific Aim 1: Establish that accumulation of
the morphine metabolite M-3-glucoronide in the gut results in opioid induced hyperalgesia and HIV induced
peripheral neuropathy in opiod using HIV patients. Specific Aim 2: Determine the role of TLR2 signaling in
morphine induced hyperalgesia and HIV associated peripheral neuropathy in the context of ART treatment.
Specific Aim 3: Treatment with genetically engineered commensal bacteria with controlled expression of B-
glucuronidase in combination with TLR2/4 antagonist will preserve small intestinal barrier integrity and attenuate
peripheral neuropathy and prolong morphine analgesia.
项目摘要
长期使用阿片类药物导致非典型疼痛(痛觉过敏)的矛盾增加。尽管其知名
由于其局限性,阿片样物质诱导的痛觉过敏的潜在机制仍然是一个显着的知识空白。
周围神经病变已成为艾滋病毒患者最常见的神经系统并发症,并且发病率很高
在感染患者中高达69.4%,值得注意的是,HIV感染的阿片类药物滥用者似乎表现出更严重的
比感染艾滋病毒的非吸毒者神经病变。此外,据报告,重复使用阿片类镇痛剂
促进HIV患者的神经性疼痛。很少有人知道ART是否会导致周围神经病变,
它在长期阿片类药物使用者中加剧。吗啡及其衍生物的主要代谢途径
在哺乳动物中,是由UDP-葡萄糖醛酸转移酶(UGT)催化的葡萄糖醛酸化。吗啡是
主要代谢为两种代谢产物,吗啡-3-葡糖苷酸(M3 G)和吗啡-6-葡糖苷酸
(M6G)(1,2)。M-3-G是啮齿类动物中产生的唯一代谢物,不具有任何镇痛作用,但具有
在最近的研究中显示激活和调节TLR信号传导。此外,抗逆转录病毒药物
特别是整合酶抑制剂,也通过UGT-葡萄糖醛酸化途径代谢。最近
研究表明,整合酶抑制剂齐多夫定的代谢产物比母体毒性更大,
化合物.在初步数据中,我们表明,慢性吗啡治疗导致显著的肠道微生物
生态失调,合成β-葡萄糖醛酸酶的细菌群落显着减少,同时
葡萄糖醛酸酶活性降低。我们在初步数据中表明,细菌群落的消耗
a)肠和血清中M-3-G积累增加
和B)减少吗啡的肠肝再循环。我们进一步证明,吗啡治疗在
HIV感染的背景导致机械性异常性疼痛(Von Frey)和
热痛觉过敏试验(Hargraves)。促炎细胞因子水平和吗啡诱导的
在TLR 2敲除小鼠中痛觉过敏显著减弱。基于这些观察,我们假设
这减少了与β葡萄糖醛酸酶合成相关的微生物群落,
暴露于高剂量吗啡导致M-3-G吗啡代谢物的积累和毒性
小肠中葡萄糖醛酸化ART有助于特定目标1:确定
吗啡代谢物M-3-葡萄糖醛酸苷在肠道中导致阿片样物质诱导的痛觉过敏和HIV诱导的痛觉过敏。
使用阿片类药物的HIV患者的周围神经病变。具体目标2:确定TLR 2信号传导在
在ART治疗的背景下,吗啡诱导的痛觉过敏和HIV相关的周围神经病变。
具体目的3:用具有B-的受控表达的基因工程化的大肠杆菌治疗
葡萄糖醛酸酶与TLR 2/4拮抗剂组合将保持小肠屏障完整性并减弱
周围神经病变和延长吗啡镇痛。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Editorial of special issue: Opioid analgesia and opioid use disorder.
特刊社论:阿片类镇痛和阿片类药物使用障碍。
- DOI:10.1016/j.expneurol.2021.113830
- 发表时间:2021
- 期刊:
- 影响因子:5.3
- 作者:Hao,Shuanglin
- 通讯作者:Hao,Shuanglin
Minnelide, a prodrug, inhibits cervical cancer growth by blocking HPV-induced changes in p53 and pRb.
- DOI:
- 发表时间:2021
- 期刊:
- 影响因子:5.3
- 作者:V. Ramakrishnan;C. de Haydu;P. Wilkinson;Urvashi Hooda;Bhuwan Giri;J. Oleas;Veronica Rive;Sabita Roy;V. Dudeja;Brian Slomovitch;A. Saluja;S. Ramakrishnan
- 通讯作者:V. Ramakrishnan;C. de Haydu;P. Wilkinson;Urvashi Hooda;Bhuwan Giri;J. Oleas;Veronica Rive;Sabita Roy;V. Dudeja;Brian Slomovitch;A. Saluja;S. Ramakrishnan
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHUANGLIN HAO其他文献
SHUANGLIN HAO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHUANGLIN HAO', 18)}}的其他基金
The molecular mechanisms of astrocytes-neurons interaction in the morphine use disorder
吗啡使用障碍中星形胶质细胞-神经元相互作用的分子机制
- 批准号:
10487821 - 财政年份:2022
- 资助金额:
$ 46.45万 - 项目类别:
Role of Gut Microbiome in HIV/Opioid Induced Peripheral Neuropathy
肠道微生物组在 HIV/阿片类药物引起的周围神经病变中的作用
- 批准号:
10163152 - 财政年份:2018
- 资助金额:
$ 46.45万 - 项目类别:
A new pathway of spinal neurons in neuropathic pain induced by HIV with opioid
脊髓神经元在 HIV 和阿片类药物诱导的神经性疼痛中的新通路
- 批准号:
10454144 - 财政年份:2018
- 资助金额:
$ 46.45万 - 项目类别:
Role of Gut Microbiome in HIV/Opioid Induced Peripheral Neuropathy
肠道微生物组在 HIV/阿片类药物引起的周围神经病变中的作用
- 批准号:
9920704 - 财政年份:2018
- 资助金额:
$ 46.45万 - 项目类别:
A new pathway of spinal neurons in neuropathic pain induced by HIV with opioid
脊髓神经元在 HIV 和阿片类药物诱导的神经性疼痛中的新通路
- 批准号:
10217077 - 财政年份:2018
- 资助金额:
$ 46.45万 - 项目类别:
A new pathway of spinal neurons in neuropathic pain induced by HIV with opioid
脊髓神经元在 HIV 和阿片类药物诱导的神经性疼痛中的新通路
- 批准号:
9788388 - 财政年份:2018
- 资助金额:
$ 46.45万 - 项目类别:
A new pathway of spinal neurons in neuropathic pain induced by HIV with opioid
脊髓神经元在 HIV 和阿片类药物诱导的神经性疼痛中的新通路
- 批准号:
9978798 - 财政年份:2018
- 资助金额:
$ 46.45万 - 项目类别:
Neuropathic mechanisms and gene therapy on opioid dependence
阿片类药物依赖的神经病理机制和基因治疗
- 批准号:
8631473 - 财政年份:2014
- 资助金额:
$ 46.45万 - 项目类别:
Neuropathic mechanisms and gene therapy on opioid dependence
阿片类药物依赖的神经病理机制和基因治疗
- 批准号:
9031097 - 财政年份:2014
- 资助金额:
$ 46.45万 - 项目类别:
Neuropathic mechanisms and gene therapy on opioid dependence
阿片类药物依赖的神经病理机制和基因治疗
- 批准号:
9247160 - 财政年份:2014
- 资助金额:
$ 46.45万 - 项目类别:
相似海外基金
Planning Study for the Development of Sigma 2 ligands as Analgesics
Sigma 2 配体镇痛药开发规划研究
- 批准号:
10641500 - 财政年份:2023
- 资助金额:
$ 46.45万 - 项目类别:
Designing and validating optimal nonaddictive analgesics using the CANDO paradigm
使用 CANDO 范式设计和验证最佳的非成瘾性镇痛药
- 批准号:
10485593 - 财政年份:2023
- 资助金额:
$ 46.45万 - 项目类别:
Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain
植物 hHv1 通道阻滞剂作为神经性疼痛镇痛药的鉴定
- 批准号:
10728526 - 财政年份:2023
- 资助金额:
$ 46.45万 - 项目类别:
Development of LPA5 Antagonists as Analgesics
LPA5 拮抗剂镇痛药的开发
- 批准号:
10638278 - 财政年份:2023
- 资助金额:
$ 46.45万 - 项目类别:
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain
设计多种配体作为非阿片类镇痛药,用于治疗慢性疼痛
- 批准号:
10621646 - 财政年份:2023
- 资助金额:
$ 46.45万 - 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10425794 - 财政年份:2022
- 资助金额:
$ 46.45万 - 项目类别:
Elucidation of the mechanism of pain suppression by exercise and development of new analgesics
阐明运动镇痛机制及开发新型镇痛药
- 批准号:
22K19602 - 财政年份:2022
- 资助金额:
$ 46.45万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics
大麻素 CB1 受体变构靶向开发非成瘾性小分子镇痛药
- 批准号:
10512672 - 财政年份:2022
- 资助金额:
$ 46.45万 - 项目类别:
A novel clinically-relevant mouse model of chronic overlapping pain conditions for screening analgesics
用于筛选镇痛药的新型临床相关慢性重叠疼痛小鼠模型
- 批准号:
10821681 - 财政年份:2022
- 资助金额:
$ 46.45万 - 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10721752 - 财政年份:2022
- 资助金额:
$ 46.45万 - 项目类别:














{{item.name}}会员




